Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

tract and period costs related to production.  The reduction in the gross margin rate is due to a $3.9 million provision for XIAFLEX inventory that may expire in 2011 prior to expected future sales to customers, and lower amortization in 2010 of deferred milestone payments, partially offset by the contribution of high margin XIAFLEX product sales and the impact of year-over-year price increases on U.S. Testim revenues.

Research and development spending for the quarter ended December 31, 2010 was $14.0 million, compared to $11.4 million for 2009.  The increase in expense results principally from the commencement of start-up activities related to the phase III XIAFLEX clinical trials for Peyronie's disease and costs related to development of a larger scale XIAFLEX production process.  

Selling, general and administrative costs for the quarter ended December 31, 2010 were $47.0 million, compared to $38.7 million in the comparable 2009 period.  The increase was primarily due to the addition of the sales and reimbursement field force and infrastructure, and promotional and training activity in support of the launch of XIAFLEX for Dupuytren's in the U.S., and higher non-cash stock-based compensation expense.

As of December 31, 2010, Auxilium had $128.2 million in cash, cash equivalents and short-term investments, compared to $142.4 million at September 30, 2010.

2010 Revenue DetailsAuxilium reported the following unaudited net revenues (all amounts in millions of dollars) for the full year 2010: Year EndYear EndIncrease12/31/201012/31/2009 (Decrease)Testim U.S. Revenue

$190.0$152.025%Testim Ex – U.S. & Contract Revenue

3.08.5(64%)Total Testim Revenue

$193.0$160.520%XIAFLEX U.S. Revenue

$14.1-n/aXIAFLEX Contract Revenue

4.33.622%Total XIAFLEX Revenue

$18.4$3.6417%Total Worldwide Revenue

$211.4$164.029%Contract Revenues represent amortization of previously receive
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 Shimadzu Scientific ... and present on LCMS and marijuana analysis at the ... March 8 to 12 at the Ernest N. Morial ... can stop by booth 3121 to discuss laboratory challenges ... company’s innovative, proven products help save time, money and ...
(Date:3/2/2015)... YORK and VANCOUVER, British Columbia ... Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical ... cannabinoid based therapies, today announced that Craig ... company overview during a live webcast at VirtualInvestorConferences.com. ... ET LINK:   http://VirtualInvestorConferences.com > click the ...
(Date:3/2/2015)... SANTA BARBARA, Calif. , March 2, 2015 ... a biotechnology company developing therapies for autoimmune and ... Trademark Office (USPTO) has issued an important new ... immune system function through the targeting of CLIP. ... the targeted peptide technology underlying VG Life Sciences, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3InMed Pharmaceuticals to Present Investor Webcast March 5 2VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Inc. (NYSE: MYL ),today announced that Mylan Pharmaceuticals ... Drug Administration (FDA) for its,Abbreviated New Drug Application (ANDA) ... 200 mg., Lamotrigine Tablets are the generic version ... $1.97 billion,for the 12 months ending Sept. 30, 2007., ...
... venture syndicate invests to advance expanding pipeline of products to ... ... Fovea Pharmaceuticals SA, a,biopharmaceutical company developing novel therapeutics for the ... in a,Series B financing from a strong, international syndicate of ...
... is,GlaxoSmithKline,s (NYSE: GSK ) response to ... Evaluative Sciences (ICES) titled,"Thiazolidinediones and Cardiovascular Outcomes ... that the ICES retrospective analysis of the ... and generates misleading,conclusions regarding acute myocardial infarction ...
Cached Biology Technology:Fovea Pharmaceuticals Completes EUR30M Series B Financing 2Fovea Pharmaceuticals Completes EUR30M Series B Financing 3Fovea Pharmaceuticals Completes EUR30M Series B Financing 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 2GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 3GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 5
(Date:2/5/2015)... 30, 2015  It is gratifying to see that ... for genomic science as a means to better understand ... treatment.  I was honored to participate in today,s White ... program. Since the 1980s my teams ... the first sequenced genome of a free living organism, ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... YORK and POINT ROBERTS, Washington ... news source covering leading sectors including technology and tech stocks, ... Privacy marketplace featuring master pickpocket and security consultant Apollo ... is stolen and talks about the Wocket™ biometric smart wallet, ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... are replaced through cell division. Researchers at Karolinska Institutet ... genetic information remains intact despite this continuous exchange of ... of the scientific journal Molecular Cell. , An adult ... which die and are replaced by cell division every ...
... the second major form of dementia. Under the ... Flanders Interuniversity Institute for Biotechnology (VIB) affiliated to ... the progranulin growth factor plays an important biological ... dementia. Because progranulin is known primarily for its ...
... scientists at Indiana University Bloomington report biochemical machinery ... weakest of scents. Even when ovary extracts were ... their mark. , A video demonstrating sperm chemotaxis ... can be downloaded at http://www.iuinfo.indiana.edu/bem/media_relations/movie.chemotaxis.mpg (Credit: Stephen ...
Cached Biology News:A protein complex that untangles DNA 2Researchers find cause of frontotemporal dementia 2Even when faint, ovary scent draws sperm cells 2